RECENT PAPERS from PubMed – November 11, 2023 – Tirzepatide and Cancer

• Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer April 18, 2026
  CONCLUSION: Adjunct GLP-1 receptor agonist therapy was associated with reduced hysterectomy risk in EIN and EC, supporting prospective fertility-sparing studies.
  Tina Yi Jin Hsieh
• Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie April 15, 2026
  No abstract
  Matteo Busti
• Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance April 14, 2026
  Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, introduces a mechanistically distinct approach within incretin-based therapies. While its efficacy is established, real-world data comparing post-marketing safety with established GLP-1 receptor agonists remain limited. This study assessed System Organ Class (SOC)-level reporting patterns for tirzepatide versus semaglutide and liraglutide using […]
  Ruxandra Cristina Marin
• Clinical Potential of GIP in Type 2 Diabetes and Obesity April 13, 2026
  Incretin-based pharmacology has revolutionized the medical treatment of type 2 diabetes and obesity. The most effective drug to date is tirzepatide, a dual incretin receptor agonist that engages both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). While the relative contributions of GIPR and GLP-1R actions to the clinical effects of […]
  Michael Nauck
• Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants April 9, 2026
  ABSTRACT: Dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely prescribed for their cardiometabolic benefits, yet their hematologic oncologic safety remains uncertain. Because hematologic malignancies are highly lethal and biologically heterogeneous, delineating drug-specific risks across histopathologic subtypes is clinically crucial. This histopathology-stratified network meta-analysis...
  Pao-Yen Lin
• Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk? April 1, 2026
  Obesity is associated with increased risk of at least 13 adult cancer types and is the second most common cause of cancer (after tobacco) in many populations. Uncertainty about the extent to which intentional weight loss leads to reduced cancer risk represents a gap in knowledge. Evidence from bariatric surgery studies shows that sustained weight […]
  Andrew G Renehan
• The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation April 1, 2026
  No abstract
  Christo Albor
• GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease March 28, 2026
  Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes and obesity, yet their actions extend beyond glycemic control and weight loss. This narrative review synthesizes current preclinical and clinical evidence examining the bidirectional relationship between glucagon-like peptide-1 (GLP-1) receptor agonists and circadian biology. A structured literature search was conducted in PubMed […]
  Ayush Gandhi
• Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects March 28, 2026
  CONCLUSIONS: Using FDA regulatory data, we compared GLP-1 RAs, GLP-1/GIP dual agonists and non-GLP-1 weight loss agents, finding the greatest weight reductions with tirzepatide and liraglutide. While efficacy outcomes were favourable, safety signals were limited by small sample sizes. Expanded real-world evidence is needed to better characterize long-term safety.
  Aishwarya Prasad
• Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro March 19, 2026
  CONCLUSION: Incretin-based therapies exert distinct, time and dose-dependent effects on skeletal muscle mitochondrial function. Tirzepatide promoted sustained improvements in mitochondrial respiration under both healthy and lipotoxic conditions, indicating potential benefits for maintaining skeletal muscle bioenergetic function. These findings underscore the need for further mechanistic studies and suggest that tirzepatide may have the potential to support […]
  Victoria Old
• Trends and projections of overweight and obesity among midlife women in the United States, 1990-2050: A sub‑study of the Global Burden of Disease 2021 March 10, 2026
  CONCLUSION: Overweight and obesity among midlife women have increased sharply with a continuing shift from overweight to obesity. Menopause-specific preventive strategies and policies promoting physical activity and healthy diet are critical to slow future increases.
  Akshaya Srikanth Bhagavathula
• Adverse events associated with tirzepatide: a focus on subgroup-specific differences February 26, 2026
  CONCLUSION: This study provides contribution for identification potential difference across subgroups, which can guide future research and more targeted monitoring strategies for tirzepatide in clinical practice. Further studies are required to validate these observations.
  Zhongming Yu
• Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors February 12, 2026
  The use of glucagon-like peptide-1 receptor agonists (GLP1-RA) for weight loss is increasing; implications in breast cancer survivors remain unclear. This retrospective cohort study evaluated treatment patterns, weight loss, and outcomes in breast cancer survivors receiving GLP1-RA at an academic institution. We evaluated patients with nonmetastatic [ductal carcinoma in situ (DCIS), stage 1-3] breast cancer […]
  Jasmine S Sukumar
• The lack of efficacy of tirzepatide in mitigating cisplatin-induced neurotoxicity and cognitive impairment in rats February 2, 2026
  INTRODUCTION: Cisplatin (CIS) is a commonly utilized chemotherapeutic agent, but its use is often accompanied by adverse effects such as neurotoxicity and cognitive impairments, collectively referred to as chemobrain. This condition impacts over 70% of cancer survivors, and currently, there are no established therapeutic interventions. This study aimed to evaluate the efficacy of tirzepatide in […]
  Hanan Mubarak Almutairi
• Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling January 29, 2026
  Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes, obesity and cardiovascular health, yet some patients remain hesitant to start these therapies due to perceptions that they are "new" or unproven. This commentary equips clinicians with practical counseling strategies to reframe the "newness" narrative and address long-term safety concerns. We provide […]
  Priyansh P Shah
• Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis January 28, 2026
  Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced the treatment of type 2 diabetes mellitus (T2DM), yet their association with cancer risk remains subject of ongoing research. Chronic pancreatitis (CP) is a well-established risk factor for pancreatic cancer, yet the impact of GLP-1 RA therapy in this high-risk population is unknown. In this study, […]
  Sarina Ailawadi
• Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service January 15, 2026
  CONCLUSIONS: Digital engagement was associated with substantially greater tirzepatide-associated weight loss in real-world practice. Integrating structured digital support with pharmacotherapy represents a promising strategy for optimizing obesity management.
  Hans Johnson
• Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method January 14, 2026
  CONCLUSION: This study uncovered new risks of tirzepatide, including AEs associated with skin, menstruation, psychiatric and nervous system. Median TTO was corrected to within a week, highlighting the need for early monitoring before clinicians prescribe tirzepatide, and special attention should be given to patients who have pre-existing digestive dysfunction, malnutrition, or a family history of […]
  Saisai Gu
• Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain January 8, 2026
  CONCLUSIONS: In the first quarter of 2025, an estimated 4.9 million adults in Great Britain-nearly one in ten-either had recently used a GLP-1 or GLP-1/GIP medication to support weight loss or were interested in doing so in the near future. A substantial minority reported using a type of GLP-1 medication that was not licensed for […]
  Sarah E Jackson
• A narrative review on tirzepatide's therapeutic potential in glycemic control and cardioprotection January 7, 2026
  Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, represents a new class of incretin-based therapy for type 2 diabetes mellitus (T2DM), obesity, and related comorbidities. This narrative review synthesizes evidence from the SURPASS, SURMOUNT, and SUMMIT clinical trial programs. Across studies, tirzepatide reduced glycated hemoglobin (HbA1c) by up to 2.5% […]
  Mrudula Thiriveedi